A new collaboration with Alcon will drive development of adjustable presbyopia-correcting IOLs, expanding market reach and validating the technology. Q2 revenue declined due to competitive trialing, prompting a revised 2026 outlook, but gross margin guidance was raised. Commercial and R&D investments are expected to support long-term growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.